Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market Company anticipates full data analysis by the end of March 2026; data to be incorporated into FDA 510(k) submission package NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the commencement of its clinical s ...

Core Insights - Intelligent Bio Solutions Inc. will participate in the 21st Annual Emerging Growth Equity Conference hosted by Noble Capital Markets on December 2-3, 2025 [1] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions [4] - The company’s Intelligent Fingerprinting Drug Screening System utilizes fingerprint sweat analysis, aiming to revolutionize portable testing with potential applications in various fields [4] - The system is designed to be hygienic and cost-effective, screening for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, with results available in under ten minutes [4] - Current customer segments outside the U.S. include construction, manufacturing, engineering, transport and logistics, mining, drug treatment organizations, and coroners [4] Conference Details - The conference will take place at Florida Atlantic University, Boca Raton, FL, with Intelligent Bio Solutions scheduled to present on December 3, 2025, at 11:00 a.m. Eastern Time [2] - A webcast recording of the presentation will be available on the company's investor relations website and Noble's website for 90 days post-event [2]